Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection.
about
Inactivation of Vibrio parahaemolyticus by antimicrobial photodynamic technology using methylene blue.In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in TaiwanSurveillance of Antibiotic Resistance among Hospital- and Community-Acquired Toxigenic Clostridium difficile Isolates over 5-Year Period in Kuwait.Treatment of Clostridium difficile infection in mice with vancomycin alone is as effective as treatment with vancomycin and metronidazole in combinationEffect of Surotomycin, a Novel Cyclic Lipopeptide Antibiotic, on Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice.Effect of Fidaxomicin versus Vancomycin on Susceptibility to Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice.Differences in the Molecular Epidemiology and Antibiotic Susceptibility of Clostridium difficile Isolates in Pediatric and Adult Patients.Clostridium difficile-associated disease: adherence with current guidelines at a tertiary medical centerVancomycin therapeutics and monitoring: a contemporary approach.Management of Clostridium difficile Infection.An in silico evaluation of treatment regimens for recurrent Clostridium difficile infection.Bezlotoxumab for the prevention of Clostridium difficile recurrence.Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections.The Addition of Intravenous Metronidazole to Oral Vancomycin is Associated With Improved Mortality in Critically Ill Patients With Clostridium difficile Infection.Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium.Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of Clostridium difficile infection.The role of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea.Surveillance of antibiotic resistance among common Clostridium difficile ribotypes in Hong Kong.Analysis of Clostridium difficile biofilms: imaging and antimicrobial treatment.Enteric microbiome profiles during a randomized Phase 2 clinical trial of surotomycin versus vancomycin for the treatment of Clostridium difficile infection.
P2860
Q35635301-D7E07F11-02B5-438F-9C2B-054E85801EB3Q35806432-839EBED0-8F1D-4AE0-887B-8D7D898021C5Q36086377-193B5100-FFBF-4A2B-AEFD-B56B4F521341Q36106735-A5C5BAFE-0F4F-4580-A77F-9D522E854DB6Q36270659-6131326A-B24A-415A-A1A2-14A11E9EE4C3Q36933317-00122B03-BB8D-4912-BAC4-FC2938590048Q37023290-0E471900-3082-491F-AD6B-72694AF2C733Q37119942-A1064B00-D0A9-4FAA-BBFC-B3C39B87AE72Q37408853-2903E658-FFDD-4164-991A-633E024A4F53Q38062923-E1300284-4D0F-4CD9-A845-2D58C9F1FD8EQ38787320-2B3DF1E8-3372-4F7C-8E73-ADEA8762A84EQ40085926-A7EFAAE5-DB7B-43B6-8F5F-55D86D9649E9Q40095035-592EE85D-FCB0-47A2-9BD2-C3FB222A2654Q40543183-1E3127C4-BC7A-47E9-A401-3DEF1EF0E287Q40889458-305130CA-47E5-4648-A5FC-95662826B1E9Q41082120-7A19DB89-6AAA-4E81-9A66-3CBBEF5FD946Q41479166-AE447E13-7E48-4F30-9C99-25BA228BF19AQ42251311-0BBB6BBD-E5AC-4535-B5AB-7D44775357B3Q47103184-95377CC6-65ED-4236-A5B3-86840C4792D0Q47446946-B7D2D198-9AE1-4766-81A6-FDB2AD82938FQ50016954-73D73448-7AF8-4650-83A8-6CEB57745767
P2860
Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Faecal pharmacokinetics of ora ...... ostridium difficile infection.
@ast
Faecal pharmacokinetics of ora ...... ostridium difficile infection.
@en
type
label
Faecal pharmacokinetics of ora ...... ostridium difficile infection.
@ast
Faecal pharmacokinetics of ora ...... ostridium difficile infection.
@en
prefLabel
Faecal pharmacokinetics of ora ...... ostridium difficile infection.
@ast
Faecal pharmacokinetics of ora ...... ostridium difficile infection.
@en
P2093
P2860
P356
P1476
Faecal pharmacokinetics of ora ...... lostridium difficile infection
@en
P2093
Jacques Pepin
Julie C Carrier
Louis Valiquette
Milagros Gonzales
Stephanie Sirard
P2860
P2888
P356
10.1186/1471-2334-10-363
P577
2010-12-30T00:00:00Z